Marginal Zone B-cell Lymphoma
10
2
2
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
20.0%
2 terminated out of 10 trials
71.4%
-15.1% vs benchmark
0%
0 trials in Phase 3/4
120%
6 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
A Phase II Study of Doxycycline in Relapsed NHL
Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)